A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
To assess the effect of two doses of Apixaban (2.5 mg BID and 5 mg BID) versus Warfarin on
the composite endpoint of major and clinically relevant non-major bleeding during the
treatment period.